If Cynata are only in the pre-clinical study stage of development it could be another 5 years before there is any treatment on the market from which Cynata could receive an income. Presumably ECQ management expect the value of the Cynata to rise in between time so that they can sell their share and make a profit. Very risky in the biotech world.
